Inogen reports FY2025 revenue $348.7M (+3.9%); net loss narrows to $22.7M; first positive adj. EBITDA in four years

Inogen Inc

2025-FY EPS reported -$0.86 revenue$348,668,000

Revenue $348.7M (+3.9% YoY); net loss $22.7M improved from $35.9M loss in 2024.
Adjusted EBITDA turned positive at $2.7M (vs -$9.5M in 2024); Q4 adj. EBITDA -$1.7M improved from -$3.6M.
Cash and equivalents $120.9M with zero debt; Board authorized $30M share repurchase program through Dec 2027.
International POC sales grew 18.4% in 2025; introduced new products Voxi 5, Aurora CPAP masks, Simeox airway clearance.
Total gross margin 44.2% in 2025 vs 46.1% in 2024 due to channel mix.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.